BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 21204914)

  • 1. Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren.
    Tapaninen T; Neuvonen PJ; Niemi M
    Br J Clin Pharmacol; 2011 May; 71(5):718-26. PubMed ID: 21204914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Grapefruit juice greatly reduces the plasma concentrations of the OATP2B1 and CYP3A4 substrate aliskiren.
    Tapaninen T; Neuvonen PJ; Niemi M
    Clin Pharmacol Ther; 2010 Sep; 88(3):339-42. PubMed ID: 20664534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intestinal OATP1A2 inhibition as a potential mechanism for the effect of grapefruit juice on aliskiren pharmacokinetics in healthy subjects.
    Rebello S; Zhao S; Hariry S; Dahlke M; Alexander N; Vapurcuyan A; Hanna I; Jarugula V
    Eur J Clin Pharmacol; 2012 May; 68(5):697-708. PubMed ID: 22124880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren.
    Tapaninen T; Neuvonen PJ; Niemi M
    Eur J Clin Pharmacol; 2010 May; 66(5):497-502. PubMed ID: 20179914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren.
    Tapaninen T; Backman JT; Kurkinen KJ; Neuvonen PJ; Niemi M
    J Clin Pharmacol; 2011 Mar; 51(3):359-67. PubMed ID: 20400651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of one-time apple juice ingestion on the pharmacokinetics of fexofenadine enantiomers.
    Akamine Y; Miura M; Komori H; Saito S; Kusuhara H; Tamai I; Ieiri I; Uno T; Yasui-Furukori N
    Eur J Clin Pharmacol; 2014 Sep; 70(9):1087-95. PubMed ID: 24903351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine.
    Dresser GK; Bailey DG; Leake BF; Schwarz UI; Dawson PA; Freeman DJ; Kim RB
    Clin Pharmacol Ther; 2002 Jan; 71(1):11-20. PubMed ID: 11823753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Major active components in grapefruit, orange, and apple juices responsible for OATP2B1-mediated drug interactions.
    Shirasaka Y; Shichiri M; Mori T; Nakanishi T; Tamai I
    J Pharm Sci; 2013 Sep; 102(9):3418-26. PubMed ID: 23794501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apple juice greatly reduces systemic exposure to atenolol.
    Jeon H; Jang IJ; Lee S; Ohashi K; Kotegawa T; Ieiri I; Cho JY; Yoon SH; Shin SG; Yu KS; Lim KS
    Br J Clin Pharmacol; 2013 Jan; 75(1):172-9. PubMed ID: 22574741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of orange juice on the pharmacokinetics of atenolol.
    Lilja JJ; Raaska K; Neuvonen PJ
    Eur J Clin Pharmacol; 2005 Jul; 61(5-6):337-40. PubMed ID: 15983823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects.
    Vaidyanathan S; Maboudian M; Warren V; Yeh CM; Dieterich HA; Howard D; Dole WP
    Curr Med Res Opin; 2008 Aug; 24(8):2313-26. PubMed ID: 18786303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects.
    Vaidyanathan S; Jermany J; Yeh C; Bizot MN; Camisasca R
    Br J Clin Pharmacol; 2006 Dec; 62(6):690-8. PubMed ID: 17118124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SLCO2B1 c.935G>A single nucleotide polymorphism has no effect on the pharmacokinetics of montelukast and aliskiren.
    Tapaninen T; Karonen T; Backman JT; Neuvonen PJ; Niemi M
    Pharmacogenet Genomics; 2013 Jan; 23(1):19-24. PubMed ID: 23151832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus.
    Zhao C; Vaidyanathan S; Yeh CM; Maboudian M; Armin Dieterich H
    Clin Pharmacokinet; 2006; 45(11):1125-34. PubMed ID: 17048976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-lasting inhibitory effect of apple and orange juices, but not grapefruit juice, on OATP2B1-mediated drug absorption.
    Shirasaka Y; Shichiri M; Murata Y; Mori T; Nakanishi T; Tamai I
    Drug Metab Dispos; 2013 Mar; 41(3):615-21. PubMed ID: 23264447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of the SLCO2B1 c.1457C > T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans.
    Imanaga J; Kotegawa T; Imai H; Tsutsumi K; Yoshizato T; Ohyama T; Shirasaka Y; Tamai I; Tateishi T; Ohashi K
    Pharmacogenet Genomics; 2011 Feb; 21(2):84-93. PubMed ID: 21280267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of body weight and gender on the pharmacokinetics, pharmacodynamics, and antihypertensive efficacy of aliskiren.
    Jarugula V; Yeh CM; Howard D; Bush C; Keefe DL; Dole WP
    J Clin Pharmacol; 2010 Dec; 50(12):1358-66. PubMed ID: 20150520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of ABCB1 haplotypes on the pharmacokinetics and renin-inhibiting effect of aliskiren.
    Tapaninen T; Neuvonen PJ; Niemi M
    Eur J Clin Pharmacol; 2010 Sep; 66(9):865-70. PubMed ID: 20496145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orange juice substantially reduces the bioavailability of the beta-adrenergic-blocking agent celiprolol.
    Lilja JJ; Juntti-Patinen L; Neuvonen PJ
    Clin Pharmacol Ther; 2004 Mar; 75(3):184-90. PubMed ID: 15001969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Major active components in grapefruit, orange, and apple juices responsible for OATP2B1-mediated drug interactions.
    Shirasaka Y; Shichiri M; Mori T; Nakanishi T; Tamai I
    J Pharm Sci; 2013 Jan; 102(1):280-8. PubMed ID: 23132664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.